AIM: To investigate influence of human leukocyte antigen (HLA) and killer immunoglobuline-like receptor (KIR) genotypes on risks of acute rejection (AR) after liver transplantation (LTX). METHODS: In this retrospective study we included 143 adult donor-recipient pairs with a minimum of 6 mo follow-up after LTX for whom DNA was available from both donor and recipients. Clinical data, all early complications including episodes and severity of AR and graft/patient survival were registered. The diagnosis of AR was based on clinical, biochemical and histological criteria. All suspected episodes of AR were biopsy confirmed. Key classical HLA loci (HLA-A, HLA-B, HLA-C and HLA-DRB1) were genotyped using Sanger sequencing. 16 KIR genes were genotyped using a novel real time PCR approach which allows for determination of the diploid copy number of each KIR gene. Immunohistochemical staining for T (CD3), B (CD20) and natural killer (NK) cells (CD56 and CD57) were performed on liver biopsies from 3 different patient groups [primary sclerosing cholangitis (PSC), primary biliary cirrhosis and non-autoimmune liver disease], 10 in each group, with similar grade of AR. RESULTS: Fourty-four (31%) patients were transplanted on the basis of PSC, 40% of them had AR vs 24% in the non-PSC group (P = 0.04). No significant impact of donor-recipient matching for HLA and KIR genotypes was detected. In the overall recipient population an increased risk of AR was detected for HLA-B*08 (P = 0.002, OR = 2.5; 95%CI: 1.4-4.6), HLA-C*07 (P = 0.001, OR = 2.4; 95%CI: 1.4-4.0) and HLA-DRB1*03 (P = 0.03, OR = 1.9; 95%CI: 1.0-3.3) and a decreased risk for HLA-DRB1*04 (P = 0.001, OR = 0.2; 95%CI: 0.1-0.5). For HLA-B*08, HLA-C*07 and DRB1*04 the associations remained evident in a subgroup analysis of non-PSC recipients (P = 0.04, P = 0.003 and P = 0.02, respectively). In PSC recipients corresponding P values were 0.002, 0.17 and 0.01 for HLA-B*08, HLA-C*07 and DRB1*04, respectively. A dosage effect of AR prevalence according to the PSC associated HLA alleles was also notable in the total recipient population. For HLA-B*08 the frequency of AR was 56% in HLA-B*08 homozygous recipients, 39% in heterozygous recipients and 21% in recipients lacking HLA-B*08 (P = 0.02). The same was observed for the HLA-C*07 allele with AR in 57%, 27% and 18% in recipients being homozygous, heterozygous and lacking HLA-C*07 respectively (P = 0.003). Immunohistochemical analysis showed similar infiltration of T, B and NK cells in biopsies with AR in all three groups. CONCLUSION: We found significant associations between the PSC-associated HLA-B*08, HLA-C*07, HLA-DRB1*03 and HLA-DRB1*04 alleles and risk of AR in liver transplant recipients.
AIM: To investigate influence of human leukocyte antigen (HLA) and killer immunoglobuline-like receptor (KIR) genotypes on risks of acute rejection (AR) after liver transplantation (LTX). METHODS: In this retrospective study we included 143 adult donor-recipient pairs with a minimum of 6 mo follow-up after LTX for whom DNA was available from both donor and recipients. Clinical data, all early complications including episodes and severity of AR and graft/patient survival were registered. The diagnosis of AR was based on clinical, biochemical and histological criteria. All suspected episodes of AR were biopsy confirmed. Key classical HLA loci (HLA-A, HLA-B, HLA-C and HLA-DRB1) were genotyped using Sanger sequencing. 16 KIR genes were genotyped using a novel real time PCR approach which allows for determination of the diploid copy number of each KIR gene. Immunohistochemical staining for T (CD3), B (CD20) and natural killer (NK) cells (CD56 and CD57) were performed on liver biopsies from 3 different patient groups [primary sclerosing cholangitis (PSC), primary biliary cirrhosis and non-autoimmune liver disease], 10 in each group, with similar grade of AR. RESULTS: Fourty-four (31%) patients were transplanted on the basis of PSC, 40% of them had AR vs 24% in the non-PSC group (P = 0.04). No significant impact of donor-recipient matching for HLA and KIR genotypes was detected. In the overall recipient population an increased risk of AR was detected for HLA-B*08 (P = 0.002, OR = 2.5; 95%CI: 1.4-4.6), HLA-C*07 (P = 0.001, OR = 2.4; 95%CI: 1.4-4.0) and HLA-DRB1*03 (P = 0.03, OR = 1.9; 95%CI: 1.0-3.3) and a decreased risk for HLA-DRB1*04 (P = 0.001, OR = 0.2; 95%CI: 0.1-0.5). For HLA-B*08, HLA-C*07 and DRB1*04 the associations remained evident in a subgroup analysis of non-PSC recipients (P = 0.04, P = 0.003 and P = 0.02, respectively). In PSC recipients corresponding P values were 0.002, 0.17 and 0.01 for HLA-B*08, HLA-C*07 and DRB1*04, respectively. A dosage effect of AR prevalence according to the PSC associated HLA alleles was also notable in the total recipient population. For HLA-B*08 the frequency of AR was 56% in HLA-B*08 homozygous recipients, 39% in heterozygous recipients and 21% in recipients lacking HLA-B*08 (P = 0.02). The same was observed for the HLA-C*07 allele with AR in 57%, 27% and 18% in recipients being homozygous, heterozygous and lacking HLA-C*07 respectively (P = 0.003). Immunohistochemical analysis showed similar infiltration of T, B and NK cells in biopsies with AR in all three groups. CONCLUSION: We found significant associations between the PSC-associated HLA-B*08, HLA-C*07, HLA-DRB1*03 and HLA-DRB1*04 alleles and risk of AR in liver transplant recipients.
Authors: William H Kitchens; Shuichiro Uehara; Catharine M Chase; Robert B Colvin; Paul S Russell; Joren C Madsen Journal: Transplantation Date: 2006-03-27 Impact factor: 4.939
Authors: Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio Journal: Proc Natl Acad Sci U S A Date: 2009-05-27 Impact factor: 11.205
Authors: Mark I McCarthy; Gonçalo R Abecasis; Lon R Cardon; David B Goldstein; Julian Little; John P A Ioannidis; Joel N Hirschhorn Journal: Nat Rev Genet Date: 2008-05 Impact factor: 53.242
Authors: Johannes R Hov; Ana Lleo; Carlo Selmi; Bente Woldseth; Luca Fabris; Mario Strazzabosco; Tom H Karlsen; Pietro Invernizzi Journal: J Hepatol Date: 2010-03-04 Impact factor: 25.083
Authors: A J Bathgate; V Pravica; C Perrey; G Therapondos; J N Plevris; P C Hayes; I V Hutchinson Journal: Transplantation Date: 2000-04-15 Impact factor: 4.939
Authors: Isabel Legaz; María R López-Álvarez; José A Campillo; María R Moya-Quiles; José M Bolarín; Jesus de la Peña; Gema Salgado; Lourdes Gimeno; Ana M García-Alonso; Manuel Muro; Manuel Miras; Clara Alonso; María R Álvarez-López; Alfredo Minguela Journal: Transplantation Date: 2013-04-27 Impact factor: 4.939
Authors: Jacob Alexander; James D Lord; Matthew M Yeh; Carlos Cuevas; Ramasamy Bakthavatsalam; Kris V Kowdley Journal: Liver Transpl Date: 2008-02 Impact factor: 5.799
Authors: P Price; C Witt; R Allcock; D Sayer; M Garlepp; C C Kok; M French; S Mallal; F Christiansen Journal: Immunol Rev Date: 1999-02 Impact factor: 12.988
Authors: Yun Ma; Haibin Su; Marianne Samyn; Diego Vergani; Giorgina Mieli-Vergani; Muhammed Yuksel; Maria Serena Longhi; Mark J McPhail; Pengyun Wang; Sanjay Bansal; Guan-Wee Wong; Jonathon Graham; Li Yang; Richard J Thompson; Derek G Doherty; Nedim Hadzic; Yoh Zen; Alberto Quaglia; Michael A Heneghan Journal: Hepatology Date: 2021-06-21 Impact factor: 17.425
Authors: Wesley Huisman; Didier A T Leboux; Lieve E van der Maarel; Lois Hageman; Derk Amsen; J H Frederik Falkenburg; Inge Jedema Journal: Front Immunol Date: 2021-03-29 Impact factor: 7.561
Authors: Christopher Bricogne; Neil Halliday; Raymond Fernando; Emmanuel A Tsochatzis; Brian R Davidson; Mark Harber; Rachel H Westbrook Journal: Liver Transpl Date: 2022-05-04 Impact factor: 6.112
Authors: K M Jamil; T J Hydes; K S Cheent; S A Cassidy; J A Traherne; J Jayaraman; J Trowsdale; G J Alexander; A-M Little; H McFarlane; M A Heneghan; M A Purbhoo; S I Khakoo Journal: Gut Date: 2016-02-17 Impact factor: 23.059